Quantbot Technologies’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Quantbot Technologies’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-13,600	Closed	-$274K	–	2144
2022 Q4	$274K	Buy	13,600 +9,700	+249%	+$209K	0.02%	783
2022 Q3	$84K	Sell	3,900 -3,747	-49%	-$102K	0.01%	1145
2022 Q2	$214K	Sell	7,647 -253	-3%	-$6.7K	0.02%	894
2022 Q1	$364K	Buy	7,900 +7,142	+942%	+$385K	0.03%	696
2021 Q4	$63K	Buy	+758	New	+$58.7K	0.01%	975
2021 Q3	–	Sell	-103	Closed	-$5K	–	1981
2021 Q2	$5K	Buy	+103	New	+$5.52K	﹤0.01%	1368

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Quantbot Technologies's ZNTL Position: Q1 2023 in Review

Quantbot Technologies sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2023, closing a stake of 13,600 shares — an estimated $274K sold.

Quantbot Technologies first reported a position in ZNTL in Q2 2021 and held it in 6 quarters. The position peaked at $364K in Q1 2022. 110 funds tracked by Wall St. Rank hold ZNTL as of Q1 2023.

Quantbot Technologies reported no remaining Zentalis Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Quantbot Technologies sold 13,600 Zentalis Pharmaceuticals shares in Q1 2023, an estimated $274K.
Quantbot Technologies first reported a position in Zentalis Pharmaceuticals in Q2 2021 and held it in 6 quarters.
Quantbot Technologies's Zentalis Pharmaceuticals position peaked at $364K in Q1 2022.
110 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2023.

Based on Quantbot Technologies's 13F filing for Q1 2023, filed 12 May 2023.